Table 2.

ORs and 95% CI by tertiles of IGF-I concentrations^*, ^#

	1	2	3	P-trend	OR cont.	P-ct
All women
All women	1.00	1.26 (0.83–1.92)	1.73 (1.14–2.63)	0.009	1.59 (1.05–2.42)	0.029
(cases/controls)	64/151	78/151	102/151
By subgroups of age at sampling**
< 25 years	1.00	1.99 (0.88–4.52)	2.69 (1.23–5.91)	0.014	2.13 (1.00–4.54)	0.050
(cases/controls)	16/50	28/50	38/51
25–30 years	1.00	0.68 (0.35–1.30)	1.16 (0.65–2.08)	0.547	1.22 (0.67–2.21)	0.512
(cases/controls)	38/69	26/69	45/70
≥ 30 years	1.00	2.22 (0.93–5.28)	1.78 (0.67–4.67)	0.232	1.99 (0.74–5.35)	0.174
(cases/controls)	10/31	24/31	19/32
By median age at diagnosis**
< 45.9 years	1.00	1.18 (0.64–2.20)	1.64 (0.94–2.84)	0.072	1.98 (1.12–3.49)	0.018
(cases/controls)	31/75	37/75	53/76
≥ 45.9 years	1.00	1.17 (0.66–2.07)	1.61 (0.88–2.96)	0.122	1.22 (0.65–2.27)	0.533
(cases/controls)	35/75	39/76	49/76
By lag time period**
<15 years	1.00	1.30 (0.52–3.29)	2.46 (1.02–5.91)	0.038	2.24 (0.98–5.14)	0.057
(cases/controls)	12/34	15/34	29/34
≥15 years	1.00	1.21 (0.76–1.93)	1.52 (0.94–2.43)	0.084	1.41 (0.87–2.30)	0.163
(cases/controls)	52/116	63/118	73/117

^*Tertiles were based on the frequency distribution of controls;

^#Continuous analysis represent risk for a change in one unit of IGF-I residuals;

^**none of the heterogeneity tests reached statistical significance.